These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34693741)

  • 1. Data monitoring committee interim reports: We must get there soon!
    DeMets DL; Wittes J
    Clin Trials; 2022 Feb; 19(1):107-111. PubMed ID: 34693741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data monitoring committees: Promoting best practices to address emerging challenges.
    Fleming TR; DeMets DL; Roe MT; Wittes J; Calis KA; Vora AN; Meisel A; Bain RP; Konstam MA; Pencina MJ; Gordon DJ; Mahaffey KW; Hennekens CH; Neaton JD; Pearson GD; Andersson TL; Pfeffer MA; Ellenberg SS
    Clin Trials; 2017 Apr; 14(2):115-123. PubMed ID: 28359194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Issues in data monitoring and interim analysis of trials.
    Grant AM; Altman DG; Babiker AB; Campbell MK; Clemens FJ; Darbyshire JH; Elbourne DR; McLeer SK; Parmar MK; Pocock SJ; Spiegelhalter DJ; Sydes MR; Walker AE; Wallace SA;
    Health Technol Assess; 2005 Mar; 9(7):1-238, iii-iv. PubMed ID: 15763038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
    Neaton JD; Grund B; Wentworth D
    Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bringing data monitoring committee charters into the sunlight.
    DeMets DL; Zarin DA; Rockhold F; Ellenberg SS; Fleming T; Wittes J
    Clin Trials; 2023 Aug; 20(4):447-451. PubMed ID: 37231737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data Monitoring Committees: Current issues.
    Fleming TR; Ellenberg SS; DeMets DL
    Clin Trials; 2018 Aug; 15(4):321-328. PubMed ID: 29629815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent data monitoring committees: an update and overview.
    Sartor O; Halabi S
    Urol Oncol; 2015 Mar; 33(3):143-8. PubMed ID: 25631301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The independent statistician model: How well is it working?
    DeMets D
    Clin Trials; 2018 Aug; 15(4):329-334. PubMed ID: 29741390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A third trial oversight committee: Functions, benefits and issues.
    Lane JA; Gamble C; Cragg WJ; Tembo D; Sydes MR
    Clin Trials; 2020 Feb; 17(1):106-112. PubMed ID: 31665920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Data Monitoring Committees and clinical trials: From scientific justification to organisation.
    Locher C; Laporte S; Derambure P; Chassany O; Girault C; Avakiantz A; Bahans C; Deplanque D; Fustier P; Germe AF; Kassaï B; Lacoste L; Petitpain N; Roustit M; Simon T; Train C; Cucherat M
    Therapie; 2024; 79(1):111-121. PubMed ID: 38103949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
    Ellenberg SS; George SL
    Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "You have to keep your nerve on a DMC." Challenges for Data Monitoring Committees in neonatal intensive care trials: Qualitative accounts from the BRACELET Study.
    Snowdon C; Brocklehurst P; Tasker RC; Ward Platt M; Elbourne D
    PLoS One; 2018; 13(7):e0201037. PubMed ID: 30048484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job.
    Evans SR; Bigelow R; Chuang-Stein C; Ellenberg SS; Gallo P; He W; Jiang Q; Rockhold F
    Ann Intern Med; 2020 Jan; 172(2):119-125. PubMed ID: 31739312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Case for Access to Data Monitoring Committee Charters.
    Zarin D; Wittes JT; Fleming TR; Rockhold F; Ellenberg S; DeMets DL
    NEJM Evid; 2024 Sep; 3(9):EVIDctw2400058. PubMed ID: 39189859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.